Filter posts

Richard Pops: A Greater Patient Voice in Drug Development

In the October issue of MedNous, Alkermes’ CEO Richard Pops writes about the move toward …

STEM Career Symposium Coming to Maryland

The Tech Council of Maryland and MdBio Foundation will soon be hosting a symposium for …

BIO Investor Forum Closing Plenary: How Fragile is the Biotech Rally After Five Positive Years?

Last week’s 13th Annual BIO Investor Forum closed on Wednesday with a plenary session asking, …

A Patient at BIO Investor Forum

“Sir?” The security guard walks to the Partnering desk, slightly confused. “Sir, there’s a man …

2014 BIO Investor Forum Fireside Chat with Nick Leschly and Chris Collins

Nick Leschly has served as bluebird bio’s president and chief executive officer since September 2010. …

Blurred Lines: Investors Explain Their Re-Thinking of Traditional Private-Only or Public-Only Invest...

The recent expansion and acceleration of the biotech stock market has seen a new willingness …

Electroceuticals and Digital Drug Delivery: Neurological Stimulation and Beyond

Some of the most experienced executives in biotechnology have begun asking themselves, “Can we foresee …

Biotech CEOs Talk JOBS Act and IPO Experiences at 2014 BIO Investor Forum

The JOBS Act has contributed to a dramatic acceleration in new biotech IPOs since its …

Fireside Chat with Ken Drazan, MD, Head of Johnson & Johnson Innovation

Day one of the BIO Investor Forum featured a Fireside Chat with Ken Drazan, MD, …

T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets

New approaches in cancer immunology are achieving promising early-stage results through novel techniques for arming …